Colorectal cancer occurs throughout the world but is most common in developed countries. As heavily populated countries such as China undergo rapid economic development, the incidence of the disease looks set to increase. An animated version of this infographic is at go.nature.com/wgiqvp. By David Holmes.

DISEASE AND DEVELOPMENT
More than half (55%) of the cases of colorectal cancer occur in developed regions, but developing countries are catching up. As the economies of countries such as Brazil, China and India grow, so does their incidence of colorectal cancer1.

HEALTH OF NATIONS
Global trends in colorectal cancer closely follow economic fortunes2. Incidence in Western Europe has been relatively flat for two decades, coinciding with a period of economic stability or decline. Meanwhile, Eastern European countries such as Slovakia have experienced rapid economic growth from a lower base, and have seen a corresponding rise in colorectal cancer.
Looking further east, Japan experienced a rapid rise in cases between 1990 and 1995, followed by almost ten years of steady or falling incidence. This period, termed ‘the lost decade’ by economists, saw falling wages and economic stagnation. By contrast, the breakneck development of Japan’s neighbour China was accompanied by a dramatic rise in colorectal cancer incidence.


SURVIVAL: NOT BLACK AND WHITE
The decline in colorectal cancer mortality in the United States has not been shared equally11. In the 1980s, African Americans died at a 13% higher rate than white Americans from the disease. Two decades later, they died at a 53% higher rate12. This disparity is caused by factors including differences in how likely they are to receive the latest treatments, and the prevalence of other health problems.

HOW IT SPREADS
Colorectal cancer affects the colon and the rectum, parts of the digestive system known as the large intestine. It usually begins as a non-cancerous growth called a polyp on the inner lining of the intestine.
References
Globocan, 2012 http://globocan.iarc.fr
International Agency for Research on Cancer, http://ci5.iarc.fr
Cancer Research UK
Chan, D S M. et al. PLoS One 6, e20456 (2011)
Larsson, S. C. & Wolk, A. Int. J. Cancer 119, 2657–2664 (2006)
US National Cancer Institute Surveillance, Epidemiology, and End Results Program, http://seer.cancer.gov
Galiatsatos, P. & Foulkes, W. D. Am. J. Gastroenterol. 101, 385–398 (2006)
Robsahm, T. E. et al. Eur. J. Cancer Prevent. 22, 492–505 (2013)
Boyle, T. et al. J. Natl Cancer Inst. 104, 1548–1561 (2012)
Ma, Y. et al. PLoS One 8, e53916 (2013)
Siegel, R., DeSantis, C. & Jemal, A. CA Cancer J. Clin. 64, 104–117 (2014)
Robbins, A. S., Siegel, R. I. & Jemal, A . J. Clin. Oncol. 30, 401–405 (2012)
Related links
Rights and permissions
About this article
Cite this article
Holmes, D. A disease of growth. Nature 521, S2–S3 (2015). https://doi.org/10.1038/521S2a
Published:
Issue Date:
DOI: https://doi.org/10.1038/521S2a
This article is cited by
-
Serum exosomal hsa-circ-0004771 modulates the resistance of colorectal cancer to 5-fluorouracil via regulating miR-653/ZEB2 signaling pathway
Cancer Cell International (2023)
-
CAD systems for colorectal cancer from WSI are still not ready for clinical acceptance
Scientific Reports (2021)
-
Elevated tumor-to-liver uptake ratio (TLR) from 18F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection
European Journal of Nuclear Medicine and Molecular Imaging (2017)